Analyzing Acurx Pharmaceuticals (ACXP) and Its Rivals

Acurx Pharmaceuticals (NASDAQ:ACXPGet Rating) is one of 940 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Acurx Pharmaceuticals to similar businesses based on the strength of its dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Valuation and Earnings

This table compares Acurx Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Acurx Pharmaceuticals N/A -$12.75 million -1.72
Acurx Pharmaceuticals Competitors $1.86 billion $249.52 million -2.83

Acurx Pharmaceuticals’ competitors have higher revenue and earnings than Acurx Pharmaceuticals. Acurx Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings for Acurx Pharmaceuticals and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acurx Pharmaceuticals 0 0 1 0 3.00
Acurx Pharmaceuticals Competitors 6508 21221 43436 872 2.54

Acurx Pharmaceuticals currently has a consensus target price of $12.00, indicating a potential upside of 359.77%. As a group, “Pharmaceutical preparations” companies have a potential upside of 122.77%. Given Acurx Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than its competitors.

Profitability

This table compares Acurx Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acurx Pharmaceuticals N/A -105.43% -97.83%
Acurx Pharmaceuticals Competitors -3,144.81% -1,459.49% -9.12%

Insider and Institutional Ownership

0.7% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Acurx Pharmaceuticals Company Profile (Get Rating)

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.